Limonin, an AMPK Activator, Inhibits Hepatic Lipid Accumulation in High Fat Diet Fed Mice

NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in pharmacology 2022-01, Vol.13, p.833705-833705
Main Authors: Wang, Si-Wei, Lan, Tian, Chen, Hang-Fei, Sheng, Hao, Xu, Chun-Yi, Xu, Li-Feng, Zheng, Fang, Zhang, Feng
Format: Article
Language:English
Subjects:
AMPK
limonin
lipid accumulation
NAFLD
Pharmacology
SREBP
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:NAFLD is the most prevalent liver disease in human history. The treatment is still limited yet. In the current study, we reported that limonin inhibited hepatic lipid accumulation and fatty acid synthesis in HFD fed mice. Using AMPK inhibitor and AMPK deficient , we revealed the effect was dependent on the activation of AMPK. We found that limonin activated AMPK through inhibition of cellular energy metabolism and increasing ADP:ATP ratio. Furthermore, the treatment of limonin induced AMPK mediated suppression of the transcriptional activity of SREBP1/2. Our study suggests that limonin may a promising therapeutic agent for the treatment of NAFLD.
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2022.833705